Clinical trial
Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
NCT00245960 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00245960 |
|---|---|
| Title | Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis |
| Official title | A RANDOMIZED, OPEN-LABEL, TWO-PERIOD STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ETANERCEPT ON SKIN AND JOINT DISEASE IN PSORIASIS SUBJECTS WITH PSORIATIC ARTHRITIS |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Psoriatic Arthritis |
| Intervention type | Drug |
| Interventions | etanercept, Placebo |
| Enrollment | 752 |
| Start date | Dec 27, 2005 |
| Primary completion | Mar 29, 2008 |
| Completion | Mar 29, 2008 |
| First posted | Oct 28, 2005 |
| Last update posted | Jan 31, 2022 |
| Countries | Argentina, Australia, Austria, Belgium, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary and 14 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: